Recently, increased expression of lipocalin-2, which stabilizes MMP-9 activity, was also proposed as potential biomarker to distinguish RAS from BOS patients and stable-LTx patients (41). This evidence concerns the gene MMP9 and Buschke-Ollendorff syndrome.